AU2018265395B2 - Compositions and methods of use of Arc capsids - Google Patents

Compositions and methods of use of Arc capsids Download PDF

Info

Publication number
AU2018265395B2
AU2018265395B2 AU2018265395A AU2018265395A AU2018265395B2 AU 2018265395 B2 AU2018265395 B2 AU 2018265395B2 AU 2018265395 A AU2018265395 A AU 2018265395A AU 2018265395 A AU2018265395 A AU 2018265395A AU 2018265395 B2 AU2018265395 B2 AU 2018265395B2
Authority
AU
Australia
Prior art keywords
arc
protein
mrna
nucleic acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018265395A
Other languages
English (en)
Other versions
AU2018265395A1 (en
Inventor
Cameron Day
Elissa PASTUZYN
Jason D. Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2018265395A1 publication Critical patent/AU2018265395A1/en
Application granted granted Critical
Publication of AU2018265395B2 publication Critical patent/AU2018265395B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2018265395A 2017-05-10 2018-05-10 Compositions and methods of use of Arc capsids Active AU2018265395B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762504370P 2017-05-10 2017-05-10
US62/504,370 2017-05-10
US201762543130P 2017-08-09 2017-08-09
US62/543,130 2017-08-09
PCT/US2018/032105 WO2018209113A1 (en) 2017-05-10 2018-05-10 Compositions and methods of use of arc capsids

Publications (2)

Publication Number Publication Date
AU2018265395A1 AU2018265395A1 (en) 2019-12-05
AU2018265395B2 true AU2018265395B2 (en) 2025-04-10

Family

ID=64104936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018265395A Active AU2018265395B2 (en) 2017-05-10 2018-05-10 Compositions and methods of use of Arc capsids

Country Status (7)

Country Link
US (1) US20210189432A1 (enExample)
EP (1) EP3621660A4 (enExample)
JP (2) JP7355382B2 (enExample)
CN (1) CN110997011A (enExample)
AU (1) AU2018265395B2 (enExample)
CA (1) CA3062614A1 (enExample)
WO (1) WO2018209113A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2019118497A1 (en) * 2017-12-11 2019-06-20 University Of Massachusetts Arc protein extracellular vesicle nucleic acid delivery platform
JP7344300B2 (ja) 2018-09-18 2023-09-13 ブイエヌブイ ニューコ インク． Ａｒｃベースのカプシドおよびその使用
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
CN114258398A (zh) 2019-06-13 2022-03-29 总医院公司 工程化的人内源性病毒样颗粒及使用其递送至细胞的方法
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
BR112023001272A2 (pt) 2020-07-24 2023-04-04 Massachusetts Gen Hospital Partículas semelhantes a vírus aprimoradas e métodos de uso das mesmas para entrega às células
CN117580949A (zh) * 2021-05-04 2024-02-20 康奈尔大学 工程化的胞外囊泡
WO2024030455A2 (en) * 2022-08-01 2024-02-08 University Of Utah Research Foundation Compositions and methods for labeling and detecting binding partners
CN118576725B (zh) * 2024-08-02 2025-06-03 中国人民解放军军事科学院军事医学研究院 一种以arc蛋白为载体的纳米颗粒及其制备方法和应用
CN120248078B (zh) * 2025-05-28 2025-11-28 中国人民解放军军事科学院军事医学研究院 一种基于arc蛋白的修饰多肽及其作为核酸递送载体的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204059B1 (en) * 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US7638269B2 (en) * 1997-02-07 2009-12-29 The Regents Of The University Of California Viral capsid assembly intermediates and methods of production
WO2009042727A1 (en) * 2007-09-24 2009-04-02 The Johns Hopkins University Immediate early gene arc interacts with endocytic machinery and regulates the trafficking and function of presenilin
WO2009097691A1 (en) * 2008-02-08 2009-08-13 University Health Network USE OF P27kip1 FOR THE PREVENTION AND TREATMENT OF HEART FAILURE
MX2011007980A (es) * 2009-02-02 2011-08-17 Okairos Ag Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas.
GB0911870D0 (en) * 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
US20130302364A1 (en) * 2010-11-10 2013-11-14 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
ES2897508T3 (es) * 2013-05-31 2022-03-01 Univ California Variantes de virus adenoasociados y métodos de uso de las mismas
US10624849B2 (en) * 2015-09-28 2020-04-21 Northwestern University Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Day et al., Arc: Building a bridge from viruses to memory, Biochem. J., 1 July 2015, Vol. 469, *

Also Published As

Publication number Publication date
US20210189432A1 (en) 2021-06-24
AU2018265395A1 (en) 2019-12-05
EP3621660A4 (en) 2021-01-20
WO2018209113A1 (en) 2018-11-15
CN110997011A (zh) 2020-04-10
JP7355382B2 (ja) 2023-10-03
CA3062614A1 (en) 2018-11-15
JP2023106451A (ja) 2023-08-01
JP7774319B2 (ja) 2025-11-21
EP3621660A1 (en) 2020-03-18
JP2020523983A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
AU2018265395B2 (en) Compositions and methods of use of Arc capsids
Pastuzyn et al. The neuronal gene arc encodes a repurposed retrotransposon gag protein that mediates intercellular RNA transfer
US10538570B2 (en) Targeted and modular exosome loading system
JP2016008217A (ja) 細胞透過のための過剰に荷電されたタンパク質
JP2014159484A (ja) 細胞透過のための過剰に荷電されたタンパク質
US20250163126A1 (en) Artificial synapses
US7132399B2 (en) Mammalian cell surface DNA receptor
US7390625B2 (en) Apoptosis-associated protein and use thereof
CN102648977B (zh) 滤泡素抑制素样蛋白1在调节钠钾atp酶活性中的用途
EP1357129A2 (en) Novel physiologically active peptide and use thereof
US7323541B2 (en) Polypeptide DNA thereof and use of the same
KR20240000561A (ko) Alpha6beta4 니코틴성 아세틸콜린 수용체에 대한 발현 시스템 및 이의 사용 방법
US7700361B2 (en) Secretory or membrane protein expressed in skeletal muscles
US20110045098A1 (en) Excitatory glycine receptors and methods
KR101857246B1 (ko) 인공 사멸세포 수용체 및 이의 용도
JP2024522850A (ja) 遺伝子の発現をモジュレートするための組成物および方法
WO2006000464A2 (de) Verfahren zum auffinden schmerzrelevanter substanzen unter verwendung schmerzrelevanter proteine

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 10 MAY 2022 TO 10 DEC 2022 IN WHICH TO PAY A CONTINUATION FEE HAS BEEN FILED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A CONTINUATION FEE HAS BEEN EXTENDED TO 10 DEC 2022

FGA Letters patent sealed or granted (standard patent)